阿哌沙班与利伐沙班治疗急性静脉血栓栓塞症的真实世界系统评价与荟萃分析
该系统评价与荟萃分析检索MEDLINE、EMBASE、Scopus和Cochrane图书馆至2019年5月的真实世界研究,比较阿哌沙班与利伐沙班治疗急性静脉血栓栓塞症(VTE)的疗效与安全性。
核心结论
- 在真实世界急性VTE患者中,阿哌沙班预防复发性VTE的疗效与利伐沙班相当,但大出血及临床相关非大出血风险更低。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE、Scopus和Cochrane图书馆至2019年5月的真实世界研究,采用随机效应模型合并风险比(RR)。
临床怎么用
- 对于急性VTE患者,阿哌沙班与利伐沙班在预防复发方面疗效相当,但阿哌沙班出血风险更低,真实世界选择抗凝药物时可参考此安全性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both apixaban and rivaroxaban have been approved for use in acute venous thromboembolism (VTE). Although indirect comparison through network meta-analyses of randomized trials have been performed to compare the efficacy and safety of these agents, further comparison between these agents was lacking until recently. We sought to systematically review and carry out a meta-analysis of studies to further compare apixaban with rivaroxaban from multiple studies done in the real-world settings. Studies comparing rivaroxaban with apixaban in patients with acute VTE were identified through electronic literature searches of MEDLINE, EMBASE, Scopus, and the Cochrane library up to May 2019. Study-specific risk ratios (RRs) were calculated and combined using a random-effects model meta-analysis. In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45). Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P = .01). Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%) in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95% CI, 0.50-0.70; P < .01). Apixaban shows equivalent efficacy in prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban.
引用
- Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019. PMID: 31405948. doi:10.1182/bloodadvances.2019000572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。